4//SEC Filing
Wave Life Sciences Ltd. 4
Accession 0000899243-15-008442
$WVECIK 0001631574operating
Filed
Nov 17, 7:00 PM ET
Accepted
Nov 18, 7:29 PM ET
Size
14.5 KB
Accession
0000899243-15-008442
Insider Transaction Report
Form 4
Transactions
- Conversion
Ordinary Shares
2015-11-16+161,663→ 3,152,440 total(indirect: See Footnote) - Purchase
Ordinary Shares
2015-11-16$16.00/sh+76,250$1,220,000→ 3,228,690 total(indirect: See Footnote) - Conversion
Series B Preferred Shares
2015-11-16−161,663→ 0 total(indirect: See Footnote)→ Ordinary Shares (161,663 underlying) - Purchase
Series B Preferred Shares
2015-08-14$12.37/sh+161,663$1,999,771→ 161,663 total(indirect: See Footnote)→ Ordinary Shares (161,663 underlying)
Tanaka Masaharu
Director10% Owner
Transactions
- Conversion
Ordinary Shares
2015-11-16+161,663→ 3,152,440 total(indirect: See Footnote) - Purchase
Series B Preferred Shares
2015-08-14$12.37/sh+161,663$1,999,771→ 161,663 total(indirect: See Footnote)→ Ordinary Shares (161,663 underlying) - Conversion
Series B Preferred Shares
2015-11-16−161,663→ 0 total(indirect: See Footnote)→ Ordinary Shares (161,663 underlying) - Purchase
Ordinary Shares
2015-11-16$16.00/sh+76,250$1,220,000→ 3,228,690 total(indirect: See Footnote)
Footnotes (3)
- [F1]The Series B Preferred Shares converted into Ordinary Shares on a one-for-one basis upon the closing of the Issuer's initial public offering of its Ordinary Shares and had no expiration date.
- [F2]Shares held by Kagoshima Shinsangyo Sousei Investment Limited Partnership ("KSS"). Masaharu Tanaka, a director of the Issuer, is the representative director of Kagoshima Development Co., Ltd., the general partner of KSS and may be deemed to beneficially own the reported securities. Pursuant to Rule 16a-1 under the Securities Exchange Act of 1934, as amended (the "Act"), Mr. Tanaka disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. The filing of this Form 4 shall not be construed as an admission that Mr. Tanaka is or was for the purposes of Section 16(a) of the Act, or otherwise, the beneficial owner of any of the reported securities.
- [F3]Share amounts reflect a 4.0415917-for-1 forward split of the Issuer's shares on November 1, 2015. The securities were purchased for $12.37 per share on a post-split basis.
Documents
Issuer
Wave Life Sciences Ltd.
CIK 0001631574
Entity typeoperating
IncorporatedSingapore
Related Parties
1- filerCIK 0001631574
Filing Metadata
- Form type
- 4
- Filed
- Nov 17, 7:00 PM ET
- Accepted
- Nov 18, 7:29 PM ET
- Size
- 14.5 KB